drugset
drugset / Trial / NCT01024062

Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC)

NCT01024062 ↗

Phase 2 Completed 60 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and the safety of paclitaxel given weekly in patients with advanced or recurrent non-small cell lung cancer

Timeline

Start
2002-12
Primary completion
2005-03
Completion
2005-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Paclitaxel Small molecule 100 mg/m2 Intravenous

Indications

non-small cell lung carcinoma